Suppr超能文献

硫唑嘌呤对肾移植受者自然杀伤细胞活性及抗体依赖性细胞毒性的抑制作用

Azathioprine suppression of natural killer activity and antibody-dependent cellular cytotoxicity in renal transplant recipients.

作者信息

Prince H E, Ettenger R B, Dorey F J, Fine R N, Fahey J L

出版信息

J Clin Immunol. 1984 Jul;4(4):312-8. doi: 10.1007/BF00915299.

Abstract

The relative effects of azathioprine (AZA) and prednisone (PRED) on natural killer (NK) activity and the antibody-dependent cellular cytotoxicity (ADCC) of K (killer) cells and the number of FcR and other lymphoid cells were examined in renal transplant recipients. In addition to both long-term (greater than 6 months) and short-term (less than 6 months) transplant recipients receiving conventional AZA-PRED therapy, an important group of long-term recipients receiving PRED but not AZA was studied for the first time. Both NK activity and ADCC are profoundly reduced in the long-term AZA-PRED group but are normal in the long-term PRED-alone (no-AZA) group. The short-term AZA-PRED group exhibits NK and ADCC levels significantly lower than normal but not as low as those of the long-term AZA-PRED group. Patient groups with low NK and ADCC also have low circulating Fc receptor-bearing (FcR) cells. A single patient in the long-term AZA-PRED group was removed from AZA therapy, and approximately 3 months was required for the patient's suppressed NK and ADCC to return to normal. These findings indicate that AZA rather than PRED is the major drug important in suppressing ADCC and NK activity in renal transplant recipients. Several months are required for combination AZA-PRED therapy to reduce these cytotoxic activities. Similarly, several months are required for suppressed ADCC and NK activity to return to normal upon discontinuation of AZA.

摘要

在肾移植受者中,研究了硫唑嘌呤(AZA)和泼尼松(PRED)对自然杀伤(NK)活性、K(杀伤)细胞的抗体依赖性细胞毒性(ADCC)以及Fc受体和其他淋巴细胞数量的相对影响。除了接受常规AZA-PRED治疗的长期(超过6个月)和短期(少于6个月)移植受者外,首次对一组重要的长期接受PRED但未接受AZA的受者进行了研究。长期AZA-PRED组的NK活性和ADCC均显著降低,但长期单独使用PRED(无AZA)组则正常。短期AZA-PRED组的NK和ADCC水平显著低于正常水平,但不如长期AZA-PRED组低。NK和ADCC水平低的患者组循环中携带Fc受体(FcR)的细胞也较少。长期AZA-PRED组中的一名患者停止使用AZA治疗,其受抑制的NK和ADCC恢复正常大约需要3个月。这些发现表明,在抑制肾移植受者的ADCC和NK活性方面,AZA而非PRED是主要的重要药物。联合使用AZA-PRED治疗需要几个月时间才能降低这些细胞毒性活性。同样,停用AZA后,受抑制的ADCC和NK活性恢复正常也需要几个月时间。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验